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STRUCTURED ABSTRACT  
Objective: To assess the risk of Ischaemic Heart Disease (IHD) and stroke (non-fatal and 
fatal) among adult ever-users of smokeless tobacco (ST).  
Design: Systematic review and meta-analysis of observational studies.  
Methods: Data sources for the review included key electronic databases and reference lists. 
Studies were included based on design  W cohort or case-control, exposure  W exclusive use of 
ST or adjusted for smoking, and outcome  W non-fatal and fatal IHD and stroke. Data 
extraction included reported measures of association (RRs or ORs) between ever use of ST 
(current or past) and CVD outcomes among non-smokers, and other study characteristics. 
Newcastle-Ottawa scale was used to assess study quality. Summary measures were 
estimated using random effects models.  
Results: Twenty studies were included in the meta-analyses. Overall, significantly increased 
risk of IHD deaths (1.15, 95% CI: 1.01-1.30) and stroke deaths (1.39, 95% CI: 1.29-1.49) was 
found among ever users of ST. We did not find an overall significant increased risk for IHD 
(1.14, 95% CI: 0.92-1.42) or stroke (1.01, 95% CI: 0.90-1.13). But geographical variations 
were marked for IHD, with significant positive association in Asian studies (1.40, 95% CI: 
1.01-1.95), and the INTERHEART study, where ST data was mainly reported from Asia (2.23, 
95% CI: 1.41-3.53). European studies did not show increased risk for non-fatal CVD.   
Conclusion: An association was found between ever use of ST and risk of fatal IHD and 
stroke, consistent with previous review. ST consumption also appears to significantly 
increase risk of non-fatal IHD among users in Asia, but not in Europe. 
 
Word count of structured abstract: 250 
Keywords: Smokeless Tobacco, Cardiovascular disease, Systematic review, Meta-analysis 
 
Page 3 of 13 
 
INTRODUCTION 
Globally, there are more than 300 million estimated Smokeless Tobacco (ST) users, with numbers 
varying widely across geographical regions.1 An overwhelming majority (nearly 89%) of these ST 
users live in the South Asian region, where approximately a third of all tobacco is consumed in 
smokeless forms.2 ST is highly addictive3 and its use is known to be associated with a range of 
adverse health effects including dental disease and precancerous oral lesions,4 cancers of the oral 
cavity , oesophagus, and pancreas, 5 as well as negative reproductive outcomes such as stillbirth, 
pre-term birth, and low birth weight.1, 6, 7 However, uncertainties exist in relation to CVD risks 
associated with the use of ST products, the link being only well established for exposure to tobacco 
in the form of cigarette smoking.8 
The last systematic review and meta-analysis on this topic was published by Boffetta and Straif in 
2009,9 and found that while ST use was associated with an increased risk of fatal myocardial 
infarction (MI) and stroke, it was not associated with an increased risk of non-fatal CVD. However 
this review was geographically restricted to studies from Europe and North America. A subsequent 
meta-analysis of Asian studies on the risk of CVD from exposure to chewed substances was 
published in 2010, and found increased risks of IHD and stroke.10 But exposure in this review was 
defined to include some products that did not necessarily contain tobacco. A further narrative 
review on ST use and coronary heart disease (CHD) was conducted in 2011.11 But this review failed 
to include cerebrovascular outcomes and counted all observational study designs including cross-
sectional studies, making it difficult to infer causality. 
To address the lack of an up-to-date systematic review and meta-analysis on the risk of CVD from 
exposure to ST, which also included studies from Asia where the use of ST is most prevalent, we 
planned to undertake one without imposing any geographical restrictions. Also, given the 
differences in the type of ST products consumed in different geographical regions, which vary by 
composition, methods of preparation and consumption,1 we hypothesised that the CVD risks 
associated with the use of these products might also be different. This paper presents the findings 
of a systematic review and a meta-analysis aimed to estimate the risk of CVD from exposure to ST, 
along with estimates for different geographical regions. 
METHODS 
The review protocol was not registered or published.  
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Search  
Search period was from January 1946 to July 2014, and updated in September 2015. Search was not 
restricted by language or geographical region, and was carried out by combining an exhaustive list 
of terms denoting various ST products with terms for specific CVD outcomes (Appendix 1).  
The databases were selected to achieve a good balance of specialised databases, and grey literature 
resources. They included MEDLINE, EMBASE, PsycINFO, CINAHL Plus, Web of Science (including 
ŽŶĨĞƌĞŶĐĞWƌŽĐĞĞĚŝŶŐƐŝƚĂƚŝŽŶ/ŶĚĞǆ ?ĂĐĐĞƐƐĞĚǀŝĂtĞďŽĨ^ĐŝĞŶĐĞ ?ŽƌĞŽůůĞĐƚŝŽŶ ? ?^ĐŽƉƵƐ ?
Cochrane Library, African Journals Online (AJOL), Latin American and Caribbean Health Sciences 
Literature (LILACS), WHO Index Medicus of the Eastern Mediterranean Region (IMEMR), WHO Index 
Medicus of the South-East Asian Region (IMSEAR), PakMediNet, IndMED, ProQuest Dissertations & 
Theses A&I, EThOS and Open Grey. Additionally, reference lists of all included studies were checked 
for any citations missed by electronic database searching.  
Selection criteria 
Cohort and case-control study designs were considered eligible for inclusion. Cross-sectional 
studies, case series and case reports were excluded. Exposure was defined as any use of ST (current 
or past), based on self-report or biochemical markers (cotinine in saliva, blood, urine, or hair). If an 
identified study included users of smoked and smokeless forms of tobacco, then it was only 
considered eligible if risks were reported for a subsample of exclusive ST users, or if smoking as a 
potential confounder was adjusted in the analysis. Studies reporting occurrence of non-fatal and/or 
fatal IHD or stroke, clearly defined according to a pre-existing diagnostic criteria were included. 
Studies that only reported  ‘ŝŶƚĞƌŵĞĚŝĂƚĞ ?ĐĂƌĚŝŽǀĂƐĐƵůĂƌŽƵƚĐŽŵĞƐƐƵĐŚĂƐďůŽŽĚ pressure or lipid 
levels were excluded. 
Data extraction  
Two researchers (AV, KS) independently carried out the first screening of titles and abstracts, and 
second screening of selected full texts to assess eligibility for inclusion. Data extraction was carried 
out using a pre-determined template by one researcher (AV), and verified by the second researcher 
(KS). The extracted information included estimates of risk (risk ratios, odds ratios) for each of the 
study outcomes, as well as other study characteristics, such as design, location, participants, 
duration, exposure and outcome definition, sample size, and adjustment for potential confounders.  
If several risk estimates were available from one study (for example, separate results for men and 
women, or for current and former ST use), we extracted these separately.  
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Quality assessment   
Methodological quality of all included studies was assessed using the Newcastle-Ottawa Scale 
(NOS).12  The scale allows a maximum score of 9, by allocating stars to judge each study on 
participant selection, comparability of groups, and ascertainment of exposure or outcome 
(Appendix 2). We did not exclude studies on the basis of quality assessment.  
Data analysis 
Meta-analyses were carried out separately for the four study outcomes using random effects 
models, on RevMan version 5.3.13 Prior to analysis, all included studies were grouped by 
geographical region (Asia, Europe, and North America). The regions were selected on the basis of 
available studies and similarities in the types of ST products predominantly consumed within each 
region. The results of cohort and case-control studies were combined in the primary analyses and 
additional analyses were performed by grouping the included studies by study design for the four 
review outcomes (IHD and stroke  W fatal and non-fatal). All findings were reported in accordance 
with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement 
(Appendix 3).14  
RESULTS   
A total of 20 studies reported in 19 publications were included in the meta-analyses (Table 1 & 
Figure 1). These included ten studies from Europe (all from Sweden),15-24 three from the North 
America (all from United States of America),25, 26 six from Asia (3 from Bangladesh, 2 from India and 
1 from Pakistan),27-32 and one large case-control study conducted in 52 countries worldwide 
(INTERHEART study).33 All studies recruited adult participants, the youngest reported age being 20 
years. Regarding gender, all European studies and two American studies were restricted to male 
participants, while the rest included both male and female participants.   
Overall, there were 9 cohort and 11 case-control studies. While all three studies from North 
America used a cohort design, studies from Europe and Asia used both case-control and cohort 
designs. None of the included studies confirmed ST use through cotinine measurements. All relied 
on self-report, using a range of exposure definitions. Eighteen studies were restricted to never 
tobacco smokers, whereas two included former smokers, controlling for smoking in the analysis.18, 
29 Fifteen of the included studies used the International Classification of Disease 34 or a similar 
diagnostic standard to categorise disease outcomes. While a diagnostic standard was not explicitly 
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mentioned in the remaining five studies, these were all hospital-based, using registered data or 
clinical diagnosis by specialists for outcome classification.   
The methodological quality of all included studies was assessed to be adequate using the NOS scale 
(Table 1), with scores ranging from 6 to 8. Four studies scored 6 points, 7 studies scored 7, and the 
highest score of 8 was given to 9 studies. All four studies that scored 6 were case-control studies, 
with the relatively lower scores resulting from inadequate description of non-response rates among 
participants.     
Among the included studies, there were 15 independent estimates for IHD, 12 for IHD deaths, 4 
estimates for stroke, and 12 for stroke deaths. The 15 independent risk estimates for IHD included 
10 estimates from Europe, 4 from Asia and 1 from 52 countries. The analysis resulted in a summary 
relative risk of 1.14 (95% CI: 0.92 to 1.42) comparing ever use of ST to never use of tobacco (Figure 
2). However, when estimated by geographical region, while studies from Sweden showed no 
significant association between ST use and risk of IHD (0.91, 95% CI: 0.83 to 1.01), studies from Asia 
showed a significantly increased risk of IHD among ST users as compared to non-tobacco users 
(1.40, 95% CI: 1.01 to 1.95). The reported increased risk was also significant in the INTERHEART 
study (OR=2.23, 95% CI: 1.41 to 3.53).  
Among the studies reporting IHD deaths, the overall relative risk for ever use of ST was 1.15 (CI: 
1.01 to 1.30), based on twelve risk estimates (Figure 3) - 2 from Asia, 5 from Europe and 5 from 
North America. However, by geographical subgroups, the increased risk of IHD deaths was only 
statistically significant for studies from Sweden (1.38, 95% CI: 1.13 to 1.67). 
On the basis of four risk estimates from Sweden, the overall relative risk of non-fatal stroke was 
1.01 (95% CI: 0.90 to 1.13) (Figure 4). In the final meta-analysis, based on 12 estimates, including 4 
from Asia, 3 from Europe, and 5 from North America (Figure 5), the overall risk of fatal stroke 
showed a significant positive effect in ST users as compared to non-users (1.39, 95% CI: 1.29 to 
1.49). Grouping results by geographical regions, the effect sizes obtained were - Asia: 1.34 (95% CI: 
1.18 to 1.52), Europe: 1.28 (95% CI: 0.98 to 1.68), and North America: 1.42 (95% CI: 1.29 to 1.57). 
Results of additional analyses (Appendix 4) by study design showed no heterogeneity between 
subgroups for 3 of the 4 study outcomes. However, significant heterogeneity was observed for the 
non-fatal IHD outcome (test for subgroup differences: df = 1, P = 0.05). 
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DISCUSSION     
This meta-analysis showed a significant increased risk of fatal IHD and stroke among ever users of 
ST compared to non-tobacco users. These conclusions were similar to Boffetta and Straif, 9 and did 
not differ much with magnitude of excess risk, despite the inclusion of two estimates from Asia for 
IHD deaths and four for stroke deaths. With regard to non-fatal outcomes, only one new study on 
risk of non-fatal stroke was identified since the previous review 15. However, this study was also 
conducted in Sweden, and like previous studies from the Nordic region, did not show an increased 
risk of stroke among ever ST users.  The analysis also showed no heterogeneity between included 
studies, thereby increasing the credibility of findings.  
On the other hand, the meta-analysis of non-fatal IHD showed considerable heterogeneity (df = 14, 
P < 0.00001). However, this heterogeneity appeared to arise more from differences in the 
geographical setting of studies (test for subgroup differences: df = 2, P < 0.0001) rather than the 
differences between the two study designs (cohort and case-control), as no subgroup differences 
were noted in this analysis on removing the Asian studies.  While results from Sweden showed no 
association between exposure and outcome, a 40% increased risk of IHD among ST users was 
calculated for studies from Asia, which was statistically significant (CI: 1.01 to 1.95). No studies from 
North America were found for this outcome category. We believe that the significant variations in 
the risk of non-fatal IHD seen by geographical regions highlight a truly increased risk among ST 
users in Asia, which is not found in Europe. We offer the following explanations to support this 
statement.  
First, the methodological quality of all the studies that were used to arrive at this conclusion was 
assessed as being sound. Second, it is possible that the significantly increased risk of non-fatal IHD 
reported in the INTERHEART study33 reflects our findings from Asia, because the use of ST was 
mainly reported from South Asia in that study. Third, reviews on the risk of cancer from ST use have 
also found significantly greater risk in Asia as compared to Western countries,35 and this finding has 
been put down to geographical variations in the ST products consumed and their levels of chemical 
carcinogens. For example, while studies from India have reported high levels of tobacco-specific 
nitrosamines (TSNA) in locally available ST products,36 much lower levels of TSNA have been 
detected in the moist snuff available in Swedish markets.37  
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Besides chemical carcinogens, the ST products in different settings are also known to vary by 
certain toxic constituents, additives, as well as methods of preparation and use,38-40 which might 
explain some of the geographical differences noted in the risk of CVD associated with their use. 
Further research is needed to assess the composition of different ST products sold worldwide,41 
specifically examining the amount of toxins present in these products that are linked with 
cardiovascular risks. Locally prevalent ST manufacturing techniques and their consumption patterns 
may also contribute to the amount of toxic exposure and more research into this field could provide 
some explanation for the observed geographical differences.42 Meanwhile, discussions around the 
biological plausibility of CVD risks associated with ST use9, 17, 24 have tended to focus on the role of 
nicotine. However, with evidence from the use of nicotine patches in patients known to have CVD 
showing improvements in existing disease conditions,43 it is likely that other chemical constituents 
of ST, in combination with nicotine, are responsible for increasing CVD risks among users.   
A study published in 2012 showing increased of heart failure from two independent Swedish 
cohorts44 was excluded after the second screening of full texts as the study outcomes did not match 
our inclusion criteria. We also excluded one study45 from the previous meta-analysis on this topic, 
because exposure did not appear to be exclusive ST use, and smoking was not controlled in the 
analysis. Even within the included studies, our risk estimates were slightly different, due to 
differences in data extraction methods. While Boffetta and Straif9 combined multiple risk estimates 
from a single study using a fixed-effect model, we extracted these as separate estimates, combining 
them finally in the meta-analyses based on random effect models. The most important difference 
however was that our analyses included studies from Asia, where ST use is most prevalent.   
The strengths of this review include the thoroughness of the search strategy, the explicit criteria set 
out for inclusion of studies with regard to study design, exposure, outcome and control of 
confounding, and the robustness of the studies included in the meta-analysis. But several 
limitations have to be considered in interpreting the results. The conclusions on potentially higher 
cardiovascular risks associated with the use of ST products in Asia are based on a small number of 
studies showing considerable heterogeneity (df = 3, I2 = 81%, P = 0.001). However publication bias 
did not appear substantial based on visual inspection of the funnel plot (Appendix 5), and the 
heterogeneity may largely be attributed to the 2012 study by Rahman et al,27 which differed from 
the other studies by recruiting both community and hospital based controls. Although the authors 
controlled for hypertension in the analysis of this study, some potential for bias remains from 
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recruitment of hospital-based controls from a hypertension clinic, ST use being positively associated 
with risk of hypertension.46  
The possibility of misclassification bias arising from differences in disease definitions cannot be 
entirely ruled out, considering diagnostic standards were not mentioned in three of the six Asian 
studies included in total.  Misclassification could also have resulted from the absence of any 
biological measurement of ST exposure (e.g. cotinine test), as ST use was documented solely 
through self-report in all included studies.  
While potential confounding by active smoking was adequately controlled by restricting the analysis 
to never smokers or adjusted estimates of risk, most of the included studies did not report alcohol 
use among study participants. Given that the cardiovascular outcomes are varyingly associated with 
differing levels of alcohol use,47 with the data available from included studies, we were unable to 
predict the effect of alcohol use on the overall results of analyses. A thorough ascertainment of 
other confounding effects such as those due to blood pressure, serum lipids, BMI, and diabetes, 
was also limited by a lack of uniformity within the included studies in adjusting for such variables 
during their analyses. For example, less than half of the studies (9 out of 20) have adjusted for the 
above classical biological risk factors. With regards to gender, most studies included in this review 
were conducted in men, with the exception of those conducted in Asia. However, sufficient data 
were not available to assess if the CVD risk conferred by ST use is different between men and 
women.  
With the available data, we found consistent evidence for an increased risk of fatal IHD and fatal 
stroke associated with ever use of ST. Geographical variations for the risk of non-fatal IHD were 
noted, with significant positive association in studies from Asia, which may be attributed to the 
content and methods of use of ST products available in these settings. Although moderate, the 
cardiovascular health implication of these findings may be relevant to a significant number of ST 
users living in South Asia, as well as South Asian diaspora communities living elsewhere who also 
use similar ST products.42, 48 Given that over three quarters of all CVD deaths take place in low- and 
middle-income countries,49 more efforts should be made to regulate ST manufacturing and 
consumption in these settings to reduce CVD risks associated with the use of this modifiable risk 
factor.  
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Table 1: Characteristics of observational studies included in the meta-analyses 
Country  Study 
period 
 
Study design (no. 
of participants) 
 
Age range of 
participants 
in years 
Exposure 
status 
Inclusion of 
smokers/ 
alcohol 
users 
Outcome 
 
ORs/RRs  
(95% CI) 
 
Comments 
 
Quality 
assessment (NOS) 
INTERHEART Study - 52 countries 
52 countries33 
 
1999-
2003 
Case-Control 
(Cases - 12461, 
Controls - 14637) 
NA Chewing 
tobacco 
No/Yes IHD 1·57 (1·24-1.99) Adjusted for 
diabetes, abdominal 
obesity, HT, exercise, 
diet 
Selection**** 
Comparability** 
Exposure* 
Studies from Asia 
Pakistan32 
 
2005-
2011 
 
Case-Control 
(Cases - 7905, 
Controls - 7458) 
20 - 80  Dippers only 
Chewers only  
No/NA IHD 
 
1.46 (1.20, 1.77)  
1.71 (1.46, 2.00)  
Adjusted for age, sex, 
region, ethnicity 
Selection**** 
Comparability** 
Exposure** 
Bangladesh28 2006-
2007 
Case-Control 
(Cases - 69, 
Controls - 138) 
20 - 49  Ever ST users No/NA IHD 
 
2.8 (1.1, 7.13) 
 
Adjusted for age, sex, 
HT  
Selection*** 
Comparability** 
Exposure* 
Bangladesh27 2010 
 
Case-Control 
(Cases - 302, 
Controls - 1510) 
40 - 75  Ever ST users No/NA IHD 
 
0.77 (0.52, 1.14) 
 
Adjusted for age, HT, 
diabetes, acute 
psycho-social stress 
Selection*** 
Comparability** 
Exposure* 
Bangladesh29 2005-
2008 
Case-Control 
(Cases - 1250, 
Controls - 246) 
20 - 100  Tobacco 
powder 
Yes/NA Stroke 
Deaths 
1.15 (0.30, 7.64) Adjusted for age, sex, 
HT, diabetes, betel 
nut, heart disease, 
smoking 
Selection*** 
Comparability** 
Exposure* 
India30 
 
1992-
1999 
Cohort (5470) > 35 Ever ST users No/NA IHD 
Deaths 
Male - 0.89 
(0.75, 1.05) 
Adjusted for age, 
education 
Selection**** 
Comparability** 
7DEOH
  
Stroke 
Deaths 
 
Female - 1.25 
(1.05, 1.49) 
Male - 1.32 
(0.94, 1.84) 
Female - 1.15 
(0.84, 1.59) 
Outcome** 
 
India31 1998-
2001 
Case-Control 
(Cases - 22000, 
Controls - 429000) 
35 - 69 Ever ST users No/No Stroke 
Deaths 
1.4 (1,2, 1.6) Adjusted for age, sex, 
education, 
urban/rural 
Selection**** 
Comparability** 
Exposure* 
Studies from Europe 
Sweden15 1998-
2005 
Cohort (16642) > 40 Current users 
Former users 
Current users 
Former users 
No/NA IHD 
 
Stroke 
 
0.85 (0.51, 1.42) 
1.07 (0.56, 2.04) 
1.18 (0.67, 2.08) 
1.35 (0.65, 2.82) 
Adjusted for age, HT, 
diabetes, cholesterol 
Selection*** 
Comparability** 
Outcome** 
 
Sweden16 1998-
2005 
Case-Control 
(Cases - 1432, 
Controls - 1810) 
45 - 70 Current users 
Former users 
Current users 
Former users 
No/NA IHD 
 
IHD 
Deaths 
0.59 (0.25, 1.4) 
1.2 (0.43, 3.2) 
1.7 (0.48, 5.5) 
1.7 (0.21, 13.6) 
Exclusive ST users  
 
Selection*** 
Comparability** 
Exposure** 
Sweden17 1978-
2004 
Cohort (118395) 35 - 65 Ever ST users No/NA IHD 
 
IHD 
Deaths 
0.91 (0.81, 1.02) 
 
1.28 (1.06, 1.55) 
Adjusted for age, 
BMI, region of 
residence 
Selection** 
Comparability** 
Outcome*** 
Sweden18 1989-
1991 
Case-Control 
(Cases - 585, 
Controls - 589) 
35 - 64 Regular ST 
users  
Yes/NA IHD 1.01 (0.66, 1.55)^ Adjusted for age, 
education, smoking 
Selection*** 
Comparability** 
Exposure* 
Sweden19 1991- Case-Control 25 - 64 Former ST No/NA IHD 1.23 (0.54, 2.82) Exclusive ST users Selection**** 
1993 (Cases - 687, 
Controls - 687) 
users 
 
 Comparability** 
Exposure** 
Sweden20 1988-
2000 
Cohort (3120) 
 
30 - 75 Daily ST users  No/NA IHD 1.41 (0.61, 3.28) 
 
 
Adjusted for BMI, 
physical activity, 
diabetes, HT 
Selection**** 
Comparability** 
Outcome** 
Sweden21 1985-
1999 
Case-Control 
(Cases - 525, 
Controls - 1798) 
30 - 60 Current users 
Former users 
No/NA IHD 0.82 (0.46, 1.46) 
0.66 (0.32, 1.36) 
 
Adjusted for BMI, 
physical activity, 
education, 
cholesterol 
Selection**** 
Comparability** 
Exposure** 
Sweden22 1974-
1985 
Cohort (135036) 35 - 65 ST users No/NA IHD 
Deaths 
 
 
Stroke 
Deaths 
 
35  W 54 years - 
2.0 (1.4, 2.9) 
55  W 65 years - 
1.2 (1.0, 1.5) 
35  W 54 years - 
1.9 (0.6, 5.7) 
55  W 65 years - 
1.2 (0.7, 1.8) 
Adjusted for age, 
region of origin 
Selection** 
Comparability** 
Outcome*** 
 
Sweden23 1985-
2000 
Case-Control 
(Cases - 276, 
Controls - 551) 
25 - 74 Regular ST 
users  
No/NA Stroke 0.87 (0.41, 1.83) 
 
Adjusted for 
diabetes, HT, 
education, marital 
status, cholesterol 
Selection**** 
Comparability** 
Exposure** 
Sweden24 1978-
2003 
Cohort (118465) 35 - 65 Ever ST users  No/NA Stroke 
Stroke 
deaths 
1.00 (0.89, 1.11) 
1.27 (0.92, 1.76) 
 
Adjusted for age, 
BMI, region of 
residence 
Selection** 
Comparability** 
Outcome*** 
Studies from North America 
USA25 1971-
1992 
Cohort (6805) 
 
25 - 74 Ever ST users No/NA IHD 
Deaths 
Male - 0.6 (0.3, 
1.2)  
Adjusted for age, 
race, poverty index 
Selection*** 
Comparability** 
  
Stroke 
Deaths 
 
Female - 1.4 (0.8, 
2.2) 
Male - 0.7 (0.2, 
2.0)  
Female - 1.0 (0.3, 
2.9) 
ratio, alcohol, 
physical activity, 
fruit/veg intake, HT, 
cholesterol, BMI 
 
Outcome*** 
USA26 1959-
1972 
Cohort CPS-I 
(77407)  
> 35 Current ST 
users 
No/Yes IHD 
Deaths 
Stroke 
Deaths 
 
1.12 (1.03, 1.21) 
1.46 (1.31, 1.64) 
 
Adjusted for age, 
race, education, 
alcohol, BMI, physical 
activity, fruit/veg 
intake, fat intake, 
aspirin  
Selection*** 
Comparability** 
Outcome*** 
USA26 1982-
2000 
Cohort CPS-II 
(114809) 
> 35 Current users 
Former users 
Current users 
Former users 
No/Yes IHD 
Deaths 
Stroke 
Deaths 
 
1.26 (1.08, 1.47) 
0.70 (0.52, 0.95) 
1.40 (1.10, 1.79) 
1.21 (0.83, 1.76) 
Adjusted for age, 
race, education, 
employment, alcohol, 
physical activity, 
fruit/veg intake, fat 
intake, BMI, aspirin 
use 
Selection*** 
Comparability** 
Outcome*** 
 
Abbreviations:  
OR, Odds Ratio; RR, Risk Ratio; CI, Confidence Interval; NOS, Newcastle-Ottawa Scale; IHD, Ischaemic Heart Disease; HT, Hypertension; NA, Not Available; 
ST, Smokeless Tobacco; BMI, Body Mass Index; CPS, Cancer Prevention Study 
FIGURE 1: SELECTION OF STUDIES IN META-ANALYSIS 
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FIGURE 2: FOREST PLOT OF RISK ESTIMATES FOR IHD AMONG EVER ST 
USERS  
 
 
 
 
IV, Inverse Variance; CI, Confidence Interval 
Alexander 2012 (a): Dippers, Alexander 2012 (b): Chewers,  
Hansson 2009 (a): Current users, Hansson 2009 (b): Former users,  
Hergens 2005 (a): Current users, Hergens 2005 (b): Former users 
Wennberg 2007 (a): Current users, Wennberg 2007 (b): Former users 
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FIGURE 3: FOREST PLOT OF RISK ESTIMATES FOR IHD DEATHS AMONG 
EVER ST USERS  
 
 
 
 
IV, Inverse Variance; CI, Confidence Interval 
 
Gupta 2005 (a): Men, Gupta 2005 (b): Women 
Bolinder 1994 (a): 35-54 years, Bolinder 1994 (b): 55-65 years 
Hergens 2005 (a): Current users, Hergens 2005 (b): Former users 
Accortt 2002 (a): Men, Accortt 2002 (b): Women 
Henley 2005 (a): CPS-I, Henley 2005 (bi): CPS-II, Current users, Henley 2005 (bii): CPS-II, Former users 
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FIGURE 4: FOREST PLOT OF RISK ESTIMATES FOR STROKE AMONG EVER ST 
USERS  
 
 
IV, Inverse Variance; CI, Confidence Interval 
 
Hansson 2009 (a): Current users, Hansson 2009 (b): Former users 
)LJXUH
FIGURE 5: FOREST PLOT OF RISK ESTIMATES FOR STROKE DEATHS AMONG 
EVER ST USERS  
 
 
 
 
IV, Inverse Variance; CI, Confidence Interval 
 
Gupta 2005 (a): Men, Gupta 2005 (b): Women 
Bolinder 1994 (a): 35-54 years, Bolinder 1994 (b): 55-65 years 
Accortt 2002 (a): Men, Accortt 2002 (b): Women 
Henley 2005 (a): CPS-I, Henley 2005 (bi): CPS-II, Current users, Henley 2005 (bii): CPS-II, Former users 
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